Aprepitant [clinicaltrials_resource:61cb8d8764b625be6b962c21424d6aad]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00107536 [clinicaltrials_resource:273f28a85c6566d76ff76854cd53b9fb]eligibility for clinicaltrials:NCT00118157 [clinicaltrials_resource:38c27da684633d4e18d079b4d14c3854]eligibility for clinicaltrials:NCT00101270 [clinicaltrials_resource:eb230e0b5e77e6f091aa9b3892782ee6]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063) [clinicaltrials:NCT00034944]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059) [clinicaltrials:NCT00035009]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) [clinicaltrials:NCT00035295]Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073) [clinicaltrials:NCT00042029]Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) [clinicaltrials:NCT00080444]2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) [clinicaltrials:NCT00090155]Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) [clinicaltrials:NCT00090207]2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) [clinicaltrials:NCT00090246]An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) [clinicaltrials:NCT00092183]Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) [clinicaltrials:NCT00092196]Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy [clinicaltrials:NCT00169572]ONO-7436 Phase II Study in Japan [clinicaltrials:NCT00212602]clinicaltrials:NCT00231777clinicaltrials:NCT00248547Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting [clinicaltrials:NCT00250744]clinicaltrials:NCT00293384Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation [clinicaltrials:NCT00314743]clinicaltrials:NCT00337727clinicaltrials:NCT00381862AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors [clinicaltrials:NCT00415103]clinicaltrials:NCT00428519Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP) [clinicaltrials:NCT00429754]clinicaltrials:NCT00475085clinicaltrials:NCT00499668clinicaltrials:NCT00571168clinicaltrials:NCT00572572clinicaltrials:NCT00588835clinicaltrials:NCT00600353clinicaltrials:NCT00619359clinicaltrials:NCT00651755clinicaltrials:NCT00659737clinicaltrials:NCT00659945Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting [clinicaltrials:NCT00699894]clinicaltrials:NCT00711555clinicaltrials:NCT00717054Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer [clinicaltrials:NCT00719173]Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers [clinicaltrials:NCT00726960]clinicaltrials:NCT00734929clinicaltrials:NCT00736073Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients [clinicaltrials:NCT00738621]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Aprepitant [clinicaltrials_resource:61cb8d8764b625be6b962c21424d6aad]
Bio2RDF identifier
61cb8d8764b625be6b962c21424d6aad
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:61cb8d8764b625be6b962c21424d6aad
identifier
clinicaltrials_resource:61cb8d8764b625be6b962c21424d6aad
title
Aprepitant
@en
type
label
Aprepitant [clinicaltrials_resource:61cb8d8764b625be6b962c21424d6aad]
@en